top of page
Human brain on a dark blue background
Broadreach Global logo white

SHARE

  • LinkedIn
  • Twitter
BIO NEUROSCIENCE 2_NO BG

14 - 15 February

2024

Amsterdam

The Netherlands

The partnering and investment summit for global leaders in CNS neuroscience drug discovery and development.

Welcome
About
Fabulous, incredibly beautiful magical landscape with a river and tulips in Amsterdam, Hol
ABOUT
Insight - Innovation - Access - Engagement - Partnering

The global partnering and investment summit for global leaders and innovators in CNS neuroscience and psychiatric drug discovery, development, platforms and technologies.

Convened by-invitation, Bio-Neuroscience is a high level, boutique
gathering of key thought leaders, innovators and decision-makers from all key stakeholder groups crucial to the discovery, development and market launch of novel therapeutics and breakthrough platforms and technologies.

High level access, serious, sustained engagement, discussion and networking with key stakeholders. Sharing models, lessons learned, solutions, ways forward and best practices. A truly curated and unique summit to facilitate business and accelerate innovation. 

 
Amsterdam by Tobias Kordt

ADVISORY BOARD

Advisory Board

We are honored by the support of our Advisory Board.

Meet them in person at the summit.

Stacie Weninger

Stacie Weninger

Executive Director, F-Prime Biomedical Research Initiative

David Reynolds

David Reynolds

Venture Partner - SV Health Investors, CEO - LoQus23 Therapeutics

Sourav Kole

Sourav Kole

Managing Director - Dolby Family Ventures

Joachim Scholpp

Joachim Scholpp

Global Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim

Kalpana Merchant, PhD

Kalpana Merchant, PhD

Adjunct Professor of Neurology, Northwestern University Feinberg School of Medicine Founder President & CSO, TransThera Consulting Co.

Juan Carlos Lopez

Juan Carlos Lopez

Managing Director, Research Grants - RTW Charitable Foundation. Formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Mark Treherne

Mark Treherne

Commercial Scientist, Entrepreneur & Investor. Chairperson - Monument Therapeutics, Talisman Therapeutics, Ubiqent, NuVision Biotherapies

Pieter van Bokhoven

Pieter van Bokhoven

Chief Scientific Officer - Amsterdam Neuroscience IAO - VUMC

Andrea Soto Padilla, M.D. PhD

Andrea Soto Padilla, M.D. PhD

Business Development - Amsterdam UMC

Pawel Świeboda

Pawel Świeboda

Founder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA.

Hakan Goker

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Christian J. Suojanen

Christian J. Suojanen

Founder & CEO - Broadreach Global, Member of the Board - European Brain Foundation

Bikes at Amsterdam Canal

SPEAKERS

Speakers

Confirmed speakers include:

Philip Scheltens

Philip Scheltens

Head of the Dementia Fund, Partner - EQT Life Sciences, Professor of Neurology - Amsterdam University Medical Center

Martien Kas

Martien Kas

President - European College of NeuroPsychopharmacology (ECNP), Professor of Behavioral Neuroscience - Groningen Institute for Evolutionary Life Sciences, University of Groningen

Olga Krylova

Olga Krylova

Director Of Business Development & Innovation - Otsuka Pharmaceutical Companies Europe

José Luis Lanciego

José Luis Lanciego

Chair - International Brain Research Organization Pan-European Committee, Head, Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program - CIMA, University of Navarra

Raúl Martín-Ruiz

Raúl Martín-Ruiz

Partner - Ysios Capital

Frédéric Destrebecq

Frédéric Destrebecq

Executive Director - European Brain Council

Jason Dichtenberg

Jason Dichtenberg

CEO – AccelBio, Executive Chairman – Evergreen Biosciences, Advisory Board Member – Alzheimers Drug Discovery Foundation, New York

Thierry Laugel

Thierry Laugel

Managing Partner - Kurma Partners

Diana Saraceni

Diana Saraceni

Co-founder & General Partner - Panakes Partners

Cillian King

Cillian King

Managing Director - EQT Life Sciences

Christian Thomsen

Christian Thomsen

Global Head of CNS BD&L - Boehringer Ingelheim

Carlos Buesa

Carlos Buesa

Founder & Chairman of the Board - Oryzon

Participants

WHO'S COMING?

Two days of sustained, interactive discussion, networking and partnering with:

Female Presenter

Industry Leaders

Senior industry leaders from pharma, large biotech and healthcare companies. Heads of therapeutic area, R&D, clinical development, biological sciences,  M&A, scouting, business development & licensing.

Andy Keller keynote

Key Opinion Leaders

Key Opinion Leaders from all stakeholder groups crucial to the successful development, approval and market launch of novel CNS neuroscience and psychiatric therapeutics, platforms and technologies.

Josh Scholpp speaking

Founders & CEOs

From startup and growth companies at the cutting edge of the future of CNS neuroscience and psychiatric drug discovery, development, advanced therapies, platforms and technologies. 

Country Flags

Government & NGOs

Public agencies, funding bodies, foundations, societies, associations, patient organizations & NGOs in CNS neurosciences and psychiatry.

FA61F746-487A-4B2A-A330-799B71754219_ed

Investors

In CNS neuroscience and psychiatric drug development, platforms and technologies.

VC and corporate venture, private equity, family offices, angels & HNW. 

Chess strategy image

Leading Advisors

A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants. 

Image by Carlos Gil
PRESENTING COMPANIES

A curated selection of the best, world-class , innovative CNS neurosciences and psychiatric  drug development companies with potential to transform healthcare, patient outcomes or markets.  Selection is by excellence and potential, not by price tag.

There is no cost to present beyond the regular startup or private company registration fees.

Presenting Companies Receive:

- A 3 minute pitch plus 3 minutes of Q&A with an expert panel of relevant investors and industry: In the plenary session.

- Exclusive post presentation meeting space:  

      - Meeting Space: one of five reserved meeting spaces                   prominently placed next to the main networking area.

      - 30 minutes in the networking break immediately                          following the presentation session.

- 2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience and psychiatric drug development and biopharma.

- Full access to the summit programme.

- Option to add an exclusive company exhibition stand.

rosarium BAR
Rosarium lobby.jpeg

VENUE

Rosarium

Amstelpark 1, Europaboulevard,

1083 HZ Amsterdam, Netherlands

Rosarium Amstelpark is one of the most presitigious meeting venues in Amsterdam, providing exceptional space for for plenary sessions, meetings and networking. With an open lobby area, wine bar, and adjacent Floriade gardens, it is a unique venue for a high level, by invitation summit like Bio-Neuroscience.  Easily accessible by car (parking available), train, or boat.

Map

CO-ORGANIZED BY

HOST PARTNER

ORGANIZING PARTNER

Organizers
logo-Amsterdam-Neuroscience-2016-1920x365
Broadreach Global logo blue

PARTNERS

Partners
The_EBC_logo SMALL
BID logo
Effectia-Logo
PAREA logo
Enquiries

GET IN TOUCH

Reach us here if you like to

  • Nominate a speaker

  • Apply to present your company or technology

  • Enquire about sponsorship & exhibition opportunities

Thanks, message received. We'll be in touch shortly.

Subscribe

Be the first to know

Subscribe and be among the first to receive all Broadreach Global updates, announcements and invitations.

Please make sure to double check your email address.

Thanks for subscribing!

shutterstock_1707864103 brain scans

A Broadreach Global Initiative

Contact us at: 

Follow us

Broadreach Global Logo white
Copyright © 2023. All rights reserved. Broadreach Global LLC.
  • LinkedIn
bottom of page